Vivani Medical, Inc. (VANI)

US — Healthcare Sector
Peers: RZLT  VIGL  OGEN  RENB  APYX  CADL  IVVD  TNON 

Automate Your Wheel Strategy on VANI

With Tiblio's Option Bot, you can configure your own wheel strategy including VANI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol VANI
  • Rev/Share 0.0067
  • Book/Share 0.0829
  • PB 17.013
  • Debt/Equity 3.7914
  • CurrentRatio 1.2976
  • ROIC -1.1387

 

  • MktCap 83533903.0
  • FreeCF/Share -0.4234
  • PFCF -3.3304
  • PE -3.2711
  • Debt/Assets 0.644
  • DivYield 0
  • ROE -1.9466

 

  • Rating D+
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Vivani Medical to Present at the Emerging Growth Conference on September 25, 2025
VANI
Published: September 24, 2025 by: GlobeNewsWire
Sentiment: Neutral

ALAMEDA, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced that it will present at the Emerging Growth Conference 86 on September 25, 2025.

Read More
image for news Vivani Medical to Present at the Emerging Growth Conference on September 25, 2025
Vivani Medical Announces Record Date for Spin-off of Cortigent Neuromodulation Subsidiary to Shareholders
VANI
Published: September 17, 2025 by: GlobeNewsWire
Sentiment: Neutral

Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology. It is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly blind

Read More
image for news Vivani Medical Announces Record Date for Spin-off of Cortigent Neuromodulation Subsidiary to Shareholders
Vivani Stock Gains After Announcing Spin-Off Plans for Cortigent Unit
VANI
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Positive

VANI is set to spin off Cortigent, aiming to sharpen its focus on drug implants and unlock long-term value for both entities.

Read More
image for news Vivani Stock Gains After Announcing Spin-Off Plans for Cortigent Unit
Vivani Medical to Present at the American Association of Pharmaceutical Scientists' “Beyond GLP1s: Where the Science will Take Business Next” Virtual Workshop
VANI
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral

ALAMEDA, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present and participate in a panel discussion at the American Association of Pharmaceutical Scientists' (AAPS) “Beyond GLP1s: Where the Science will Take Business Next” Virtual Workshop, taking place from May 13-14, 2025.

Read More
image for news Vivani Medical to Present at the American Association of Pharmaceutical Scientists' “Beyond GLP1s: Where the Science will Take Business Next” Virtual Workshop
Vivani Medical Announces $8.25M Private Placement Equity Financing
VANI
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral

Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated development of NPM-139, Company's once or twice-yearly GLP-1 (semaglutide) implant under development for chronic weight management ALAMEDA, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced that it has entered into a securities purchase agreement to issue and sell an aggregate of 7,366,071 shares, each at a price of $1.12 per share, expected to result in gross proceeds of approximately $8.25 million in a private placement.

Read More
image for news Vivani Medical Announces $8.25M Private Placement Equity Financing
What Makes Vivani Medical (VANI) a New Buy Stock
VANI
Published: March 17, 2025 by: Zacks Investment Research
Sentiment: Positive

Vivani Medical (VANI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Read More
image for news What Makes Vivani Medical (VANI) a New Buy Stock

About Vivani Medical, Inc. (VANI)

  • IPO Date 2014-11-19
  • Website https://www.vivani.com
  • Industry Medical - Devices
  • CEO Adam Mendelsohn
  • Employees 37

Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.